Compare UNCY & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | VBF |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 169.8M |
| IPO Year | 2021 | 1995 |
| Metric | UNCY | VBF |
|---|---|---|
| Price | $4.59 | $14.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $29.60 | N/A |
| AVG Volume (30 Days) | ★ 767.1K | 84.2K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52,701.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $14.04 |
| 52 Week High | $8.74 | $15.86 |
| Indicator | UNCY | VBF |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 26.00 |
| Support Level | $3.93 | N/A |
| Resistance Level | $5.86 | $15.21 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 38.32 | 17.78 |
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.